FAM
Fred Alger Management Portfolio holdings
AUM
$22.3B
1-Year Return
57.87%
This Quarter Return
+38%
1 Year Return
+57.87%
3 Year Return
+264.72%
5 Year Return
+406.03%
10 Year Return
+1,631.73%
AUM
$30.4B
AUM Growth
+$7.6B
(+33%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
0.73%
Top 10 Holdings %
Top 10 Hldgs %
34%
Holding
622
New
73
Increased
196
Reduced
171
Closed
128
Top Buys
| 1 |
T-Mobile US
TMUS
|
$436M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$150M |
| 3 |
Shake Shack
SHAK
|
$147M |
| 4 |
Datadog
DDOG
|
$140M |
| 5 |
Lowe's Companies
LOW
|
$109M |
Top Sells
| 1 |
Microsoft
MSFT
|
$206M |
| 2 |
NVIDIA
NVDA
|
$160M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$153M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$136M |
| 5 |
CrowdStrike
CRWD
|
$118M |
Sector Composition
| 1 | Technology | 33.43% |
| 2 | Healthcare | 21.84% |
| 3 | Consumer Discretionary | 15% |
| 4 | Communication Services | 9.98% |
| 5 | Financials | 8.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Novo Nordisk
NVO
$245B
| $2.16M | 0.01% |
66,000
+6,000
| +10% | +$196K |
|
302
Workday
WDAY
$62B
| $2.12M | 0.01% |
11,292
+9,319
| +472% | +$1.75M |
|
303
Centene
CNC
$14.1B
| $2.03M | 0.01% |
31,908
-121,569
| -79% | -$7.73M |
|
304
Pfizer
PFE
$141B
| $1.98M | 0.01% |
63,669
-87,419
| -58% | -$2.71M |
|
305
Blackstone
BX
$132B
| $1.96M | 0.01% |
34,544
-173
| -0.5% | -$9.8K |
|
306
Axsome Therapeutics
AXSM
$6.22B
| $1.89M | 0.01% |
23,000
+4,000
| +21% | +$329K |
|
307
Bristol-Myers Squibb
BMY
$95.7B
| $1.89M | 0.01% |
32,181
-271,931
| -89% | -$16M |
|
308
Rockwell Automation
ROK
$38.2B
| $1.87M | 0.01% |
8,788
-8,139
| -48% | -$1.73M |
|
309
CME Group
CME
$94.4B
| $1.87M | 0.01% |
11,477
-292,223
| -96% | -$47.5M |
|
310
Woodward
WWD
$14.4B
| $1.86M | 0.01% |
23,945
+19,908
| +493% | +$1.54M |
|
311
Iovance Biotherapeutics
IOVA
$887M
| $1.86M | 0.01% |
67,602
+44,602
| +194% | +$1.22M |
|
312
FIVE9
FIVN
$2.03B
| $1.84M | 0.01% |
16,645
-40,394
| -71% | -$4.47M |
|
313
Molina Healthcare
MOH
$9.43B
| $1.78M | 0.01% |
+10,000
| New | +$1.78M |
|
314
Ares Management
ARES
$38.8B
| $1.74M | 0.01% |
43,705
+4,772
| +12% | +$189K |
|
|
CCXI
315
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.73M | 0.01% |
30,000
| – | – |
|
316
Core Laboratories
CLB
$587M
| $1.68M | 0.01% |
+82,740
| New | +$1.68M |
|
317
ADC Therapeutics
ADCT
$389M
| $1.64M | 0.01% |
+35,000
| New | +$1.64M |
|
318
Altria Group
MO
$111B
| $1.62M | 0.01% |
41,374
| – | – |
|
319
Halozyme
HALO
$8.7B
| $1.61M | 0.01% |
60,000
+2,000
| +3% | +$53.6K |
|
320
Marriott International Class A Common Stock
MAR
$71.8B
| $1.6M | 0.01% |
+18,607
| New | +$1.6M |
|
321
West Pharmaceutical
WST
$18.1B
| $1.59M | 0.01% |
7,000
+6,884
| +5,934% | +$1.56M |
|
322
NextEra Energy, Inc.
NEE
$146B
| $1.57M | 0.01% |
26,192
| – | – |
|
323
Sanofi
SNY
$112B
| $1.53M | 0.01% |
+30,000
| New | +$1.53M |
|
324
Moelis & Co
MC
$5.25B
| $1.51M | 0.01% |
48,589
+5,490
| +13% | +$171K |
|
325
TG Therapeutics
TGTX
$5.11B
| $1.46M | ﹤0.01% |
75,000
+34,000
| +83% | +$662K |
|